49 research outputs found
Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure
No full textBackground: Congestive heart failure (CHF) is a common cause of atrial fibrillation (AF). Oxidative stress and inflammation (profibrotic) and peroxisome proliferator-activated receptor-alpha (PPAR-alpha, antifibrotic) factors may be involved in CHF-related remodeling. We evaluated the effects of simvastatin (antioxidant, anti-inflammatory) and fenofibrate (PPAR-alpha activator) on CHF-related atrial remodeling. Methods and results: Dogs were subjected to 2-week ventricular tachypacing (VTP) in the absence and presence of simvastatin (20 or 80 mg/day) or fenofibrate. Induced AF duration (DAF) was increased by VTP from 36 +/- 14 (non-paced controls) to 1005 +/- 257 s (p Conclusions: CHF-induced atrial structural remodeling and AF promotion are attenuated by simvastatin, but not fenofibrate. Statin-induced inhibition of profibrotic atrial fibroblast responses and attenuation of left-ventricular dysfunction may contribute to preventing the CHF-induced fibrotic AF substrate. (c) 2007 European Society of Cardiology. Published by Elsevier B.V. All rights reserved
Association of cystatin C level and cardiovascular prognosis for patients with preexisting coronary heart disease: a meta-analysis
No full text
A point mutation in the putative ATP binding site of the pseudorabies virus US3 protein kinase prevents Bad phosphorylation and cell survival following apoptosis induction
No full textIncorporation and degradation by kidney lysosomes of cystatin alpha injected intravenously
No full textExpression of the Pseudorabies Virus Latency-Associated Transcript Gene during Productive Infection of Cultured Cells
No full textDecreased metastatic spread in mice homozygous for a null allele of the cystatin C protease inhibitor gene
No full textPurification and properties of 2-hydroxy-6-oxo-2,4-heptadienoate hydrolase from two strains of Pseudomonas putida
No full textCystatin C and risk of mortality among patients undergoing percutaneous coronary intervention
No full textn/
